Cancer Research The Future of Cancer Research: Science and Patient Impact Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, N.
Right arrow Articles by Brodt, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, N.
Right arrow Articles by Brodt, P.
[Cancer Research 66, 3062-3070, March 15, 2006]
© 2006 American Association for Cancer Research

Cell, Tumor, and Stem Cell Biology

The Secretory Leukocyte Protease Inhibitor Is a Type 1 Insulin-Like Growth Factor Receptor–Regulated Protein that Protects against Liver Metastasis by Attenuating the Host Proinflammatory Response

Ni Wang1, Thusanth Thuraisingam2, Lucia Fallavollita1, Aihao Ding3, Danuta Radzioch2 and Pnina Brodt1,2

1 Department of Surgery, Royal Victoria Hospital, McGill University Health Centre, McGill University, 2 Department of Experimental Medicine, Montreal, Quebec, Canada; and 3 Department of Microbiology and Immunology, Weill Medical School of Cornell University, New York, New York

Requests for reprints: Pnina Brodt, Surgical Labs, Royal Victoria Hospital, Room H6.25, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1. Phone: 514-934-1934, ext. 36692; Fax: 514-843-1411; E-mail: pnina.brodt{at}muhc.mcgill.ca.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The secretory leukocyte protease inhibitor (SLPI) can attenuate the host proinflammatory response by blocking nuclear factor {kappa}B (NF-{kappa}B)–mediated tumor necrosis factor {alpha} (TNF-{alpha}) production in macrophages. We have previously shown that highly metastatic human and mouse carcinoma cells, on their entry into the hepatic microcirculation, trigger a rapid host proinflammatory response by inducing TNF-{alpha} production in resident Kupffer cells. Using GeneChip microarray analysis, we found that in mouse Lewis lung carcinoma subclones, SLPI expression was inversely correlated with tumor cell ability to induce a proinflammatory response and metastasize to the liver and with type 1 insulin-like growth factor receptor expression levels. To establish a causal relationship between SLPI expression and the metastatic phenotype, we generated, by transfection, multiple clones of the highly metastatic subline (H-59) that overexpress SLPI. We show here that the ability of these cells to elicit a host proinflammatory response in the liver was markedly decreased, as evidenced by reduced TNF-{alpha} production and vascular E-selectin expression, relative to controls. Moreover, these cells formed significantly fewer hepatic metastases (up to 80% reduction) as compared with mock-transfected controls. Our findings show that SLPI can decrease the liver-metastasizing potential of carcinoma cells and that this protective effect correlates with a decrease in the production of hepatic TNF-{alpha} and E-selectin. They suggest that factors that attenuate the host proinflammatory response may have a therapeutic potential in the prevention of liver metastasis. (Cancer Res 2006; 66(6): 3062-70)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The secretory leukocyte protease inhibitor (SLPI) is an 11.7-kDa, nonglycosylated, single-chain protein that is produced by different cell types including lung epithelial cells, secretory cells of the salivary glands, and various host inflammatory and immune cells such as macrophages, neutrophils, and B lymphocytes (1–3). It was initially identified as a serine proteinase inhibitor with activity against neutrophil elastase, cathepsin G, trypsin, and chymotrypsin (4) and its major function was thought to be tissue protection from inflammation-induced damage caused by these enzymes. More recently, it has been recognized as an anti-inflammatory modulator with a broad range of activities that may or may not be related to its antiprotease functions. These include increasing host resistance to bacterial and viral infection (5, 6), down-regulation of prostaglandin E2 and matrix metalloproteinase-1 and -9 production (7), and attenuation of the macrophage response to lipopolysaccharide (LPS; ref. 8).

Whereas the precise mechanisms mediating these various activities have not been fully elucidated, the evidence suggests that they are related to the ability of SLPI to inhibit NF-{kappa}B activation and, as a result, reduce tumor necrosis factor {alpha} (TNF-{alpha}) production and attenuate TNF-{alpha}-induced inflammation in response to various stimuli (3, 9–11). Collectively, these activities have identified SLPI as an endogenous regulator of innate host immunity and inflammation of which the main function is to provide tissue protection from the extreme effects and damage caused by an excessive inflammatory response.

TNF-{alpha} is a key cytokine in the acute phase of inflammation (12). It also contributes to malignant progression (12–14). Direct evidence for the involvement of TNF-{alpha} in malignancy comes from the observation that mice lacking the TNF-{alpha} gene are resistant to skin carcinogenesis (15). In other studies, it has been shown that the i.p. administration of recombinant TNF-{alpha} in mice led to a significant increase in the number of liver metastases, in several models including metastatic lymphoma (16) and solid tumors (17–19). This effect may be mediated through several mechanisms including TNF-{alpha}-induced tumor cell motility and increased production of metalloproteinases, resulting in enhanced invasion and angiogenesis (13, 20). In addition, TNF-{alpha} can induce the expression of several adhesion receptors on vascular endothelial cells. These include E- and P-selectin that can mediate tumor-endothelial cell adhesion and trigger a cascade of cellular interactions that are required for tumor cell transmigration (19–24).

In a series of studies, we have previously shown that tumor cell entry into the hepatic microvasculature can trigger a rapid proinflammatory cascade that begins with increased local TNF-{alpha} and interleukin 1 (IL-1) production by activated Kupffer cells and leads to up-regulated expression of E-selectin and other vascular adhesion receptors, such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), on the hepatic sinusoidal vessels (22, 25). Furthermore, a blockade of TNF-{alpha} mediated E-selectin induction by mouse-specific C-raf antisense oligonucleotides or the inhibition of E-selectin function by specific neutralizing antibodies resulted in a marked reduction in the number of experimental liver metastases following the injection of human colorectal carcinoma CX-1 and mouse Lewis lung carcinoma derived H-59 cells, respectively (21, 23). These results showed that E-selectin plays an important role in the establishment of hepatic metastases by these tumor cells. Taken together, these results suggested that metastatic tumor cells can trigger an endogenous, local host proinflammatory response that can promote liver metastasis through the up-regulation of vascular adhesion receptors (22, 23, 25). This response was tumor specific and could not be observed with a Lewis lung carcinoma subline (M-27) that is poorly metastatic to the liver (22, 25).

Using RNA chip microarray analysis to identify genes that are differentially expressed in the two carcinoma cell lines of common origin, H-59 and M-27, with divergent potentials to induce a proinflammatory response and metastasize to the liver, we identified SLPI as a potentially protective gene against liver metastasis. The objective of this study was to evaluate the antimetastatic function of SLPI and explore its role in the regulation of the host proinflammatory response to liver-invading tumor cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell lines. The origin and metastatic properties of in vivo derived Lewis lung carcinoma subclones H-59 and M-27 were previously described in detail (26). H-59 cells are highly metastatic, primarily to the liver. M-27 cells are moderately metastatic to the lung and do not metastasize to the liver. To produce green fluorescent protein (GFP)–expressing H-59 tumor cells, the cells were transduced with the vLTR-GFP retrovirus as we previously described (25, 27). The control macrophage cell line ANA-1 was derived from the bone marrow of C57BL/6 mice and previously characterized in detail (28). It was used here as a reference cell line in assays characterizing the secretory properties of the carcinoma lines. All cells were maintained in RPMI 1640 supplemented with 10% heat-inactivated FCS (Hyclone, Logan, UT) in a humidified incubator containing 5% CO2.

Plasmids and transfection. Metastatic H-59 carcinoma cells were transfected with the pCDNA3.1 vector (Invitrogen, Carlsbad, CA) encoding a full-length mouse SLPI cDNA. Clones were selected in culture medium containing 400 µg/mL G418 (Life Technologies, Inc., Grand Island, NY). Mock-transfected cells were generated by transfection with the pcDNA3.1/neo plasmid under identical conditions. M-27IGF-IR cells and M-27mock were generated as we previously described in detail (29). All transfected clones were maintained in culture medium containing 200 µg/mL G418 and analyzed by reverse transcription-PCR (RT-PCR) and Western blotting to ascertain SLPI mRNA and protein expression and secretion, respectively.

RT-PCR. Total cellular RNA was extracted from snap-frozen liver fragments using Trizol (Invitrogen) according to the instructions of the manufacturer. Two micrograms of total RNA were reverse transcribed using the Thermoscript RT-PCR System (Invitrogen) with Random Hexamers as primer. The mixture was incubated for 10 minutes at 25°C, then for 45 minutes at 55°C, and finally for 5 minutes at 85°C. The upstream and downstream primers used were as follows: for TNF-{alpha}, 5'-GCAGGTCTACTTTGGAGTCATTGC-3' and 5'-TCCCTTTGCAGAACTCAGGAATGG-3' (expected product, 331 bp): for E-selectin, 5'-GTACTACAATGCCTCCAGTGAG-3' and 5'-CACAGCTTGCTCACAGTTG-3' (expected product, 469 bp); for SLPI, 5'-TCACGGTGCTCCTTGCTCTG-3' and 5'-CGTCCCTCTGGCAGACATTG-3' (expected product, 300 bp); and for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5'-GGTGAAGGTCGGTGTGAACGGATTT-3' and 5'-AATGCCAAAGTTGTCATGGATGACC-3' (expected product, 520 bp). cDNA amplification was done with the Platinum Taq DNA polymerase kit (Invitrogen) using 30 cycles of amplification for SLPI, TNF-{alpha}, and E-selectin and 26 cycles for GAPDH, each for 30 seconds at 94°C, 30 seconds at 63°C (E-selectin), 58°C (TNF-{alpha}, GAPDH), or 56°C (SLPI), and 30 seconds at 72°C, followed by a 7-minute incubation at 72°C. The amplified DNA fragments were analyzed by electrophoresis on a 1.5% agarose gel without further purification.

Real-time PCR. RNA extraction and reverse transcription were done as described above. The cDNA amplification was done in a LightCycler (Roche Applied Science, Indianapolis, IN) using the LightCycler FastStart DNA Master SYBR Green I kit (Roche Applied Science) and a standard PCR reaction mixture containing 3 mmol/L MgCl2, 0.5 µmol/L each of the TNF-{alpha} and GAPDH primers, and 2 µL of cDNA. Twenty microliters of this reaction mixture were initially incubated for 10 minutes at 95°C to denature the DNA and activate the FastStart Taq DNA. Amplification was then done using 46 cycles of denaturation (95°C, 10 seconds, ramp rate 20°C/s), annealing (58°C, 5 seconds, ramp rate 20°C/s), and extension (72°C, 26 seconds, ramp rate 20°C/s). A single fluorescence reading was taken at each extension step. The crossing points, marking the cycle when the fluorescence of a given sample significantly exceeded the baseline signal, were recorded and expressed as a function of cycle number. The data were analyzed using the LightCycler software.

Western blot assay. Subconfluent monolayers (~8 x 106 cells) were washed extensively to remove serum and the cells were cultured in serum-free medium for 48 hours at 37°C. To assess the levels of secreted SLPI, the conditioned media were first concentrated 40 or 100-fold and then analyzed by Western blotting. Fifty micrograms of protein were loaded per lane of a 15% SDS-polyacrylamide gel and the separated proteins transferred onto nitrocellulose membranes and probed with a rabbit polyclonal antibody to mouse SLPI as previously described (3). A peroxidase-conjugated affiniPure donkey anti-rabbit immunoglobulin G (Cedarlane, Hornby, Ontario, Canada) was used as secondary antibody at a dilution of 1:10,000 and the enhanced chemiluminescence system used to visualize the protein bands.

Analysis of the activity of SLPI secreted by gene-transfected H-59 cells. To confirm that H-59 cells transfected with the SLPI gene secreted an active protein that is able to modify TNF-{alpha} production by macrophages, an in vitro assay was established. Serum-free conditioned media were harvested from 24-hour cultures of control, mock-transfected, and SLPI-transfected H-59 cells. The media were filtered to ensure that they were cell-free and sterile and added (or not) to monolayers of ANA-1 cells that were preseeded 24 hours earlier in 24-well plates at a density of 5 x 105 per well for a 1-hour incubation at 37°C. To each well, 100 ng/mL LPS were then added for a 6 hours incubation, the ANA-1 cell supernatants harvested, and TNF-{alpha} levels analyzed by ELISA using the protocol described in detail elsewhere (25, 30).

Cell invasion assay. Tumor cell invasion was assessed in vitro using Matrigel essentially as we previously described (31). Briefly, the assay was done using 8-µm pore size Nuclepore filters (Transwell, Corning, Acton, MA) that were precoated with 0.23 mg/mL Matrigel (Collaborative Research, Bedford, MA). To each filter, 5 x 105 cells were added and insulin-like growth factor (IGF-I; 10 ng/mL) was used to induce cell motility. Triplicate filters were used for each cell type and assay condition and 20 random fields were counted per filter.

Intrasplenic/portal injections. C57BL/6 female mice (6-10 weeks old) were anesthetized by an i.m. injection of 0.5 mg/kg Acepromazine followed by an i.m. injection of ketamine/xylazine at final concentrations of 100 and 10 mg/kg, respectively. The spleens were exposed through a small abdominal incision, 105 or 106 tumor cells in 0.1 mL saline or saline alone were injected into the spleen, and the animals were splenectomized 1 minute later. Fourteen days post inoculation of 105 tumor cells, the animals were euthanized, the livers removed, and the hepatic metastases enumerated immediately without prior fixation of the livers. For measurement of TNF-{alpha} and E-selectin mRNA, livers were harvested at different time intervals, ranging from 20 minutes to 24 hours post inoculation of 2 x 106 tumor cells. Liver fragments used for mRNA extraction were snap-frozen in liquid N2 and then stored at –80°C until they were used. All the procedures were carried out in accordance with the policies and regulations of the McGill Animal Care facility.

Immunohistochemistry and fluorescence microscopy. Following tumor cell injection, the livers were perfused with 50 mL of a 4% paraformaldehyde solution, fixed for 48 hours in the same fixative, transferred into a 30% sucrose solution for 4 days, and then placed in optimum cutting temperature medium before freezing at –80°C. Immunhistochemistry was done on 7-µm cryostat sections. The sections were incubated first in a blocking solution (1% Donkey serum, 1% goat serum, 0.1% bovine serum albumin, 0.1% Triton X-100 in PBS) for 30 minutes and then overnight at 4°C with a rat monoclonal antibody to murine E-selectin (PharMingen, Mississauga, Ontario, Canada), used at a dilution of 1:50. After several washes with PBS, the sections were incubated for 1 hour with an Alexa 568 goat anti-rat antibody (Molecular Probes, Inc., Eugene, OR) at a dilution of 1:200 and mounted in Prolong Gold antifade reagent (Molecular probes). Representative digitized images were acquired using a Zeiss microscope. To monitor tumor cell retention in the liver during the first 6 hours following injection, mice were inoculated by the intrasplenic route with 106 GFP+ tumor cells and the livers removed at different time intervals thereafter, ranging from 20 minutes to 6 hours, and processed for fluorescence microscopy as described above. Representative digitized images were acquired using the Zeiss microscope and the fluorescent tumor cells were enumerated.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Identification of SLPI as a potential regulatory gene in liver metastasis. Using Affymetrix 74A DNA microarray chips, we did a comparative gene expression analysis of carcinoma cells with divergent potentials to metastasize to the liver. RNA was extracted from liver-metastatic H-59 and nonmetastatic M-27 carcinoma cells. Among several interesting candidate genes, we found that SLPI mRNA was expressed at dramatically higher levels (>2 log difference in gene expression) in M-27 as compared with H-59 cells. Using this analysis, we were also able to confirm our previously published findings that the IGF-I receptor (IGF-IR) was differentially expressed in these two cell lines (32, 33).

Previously we have shown that in this carcinoma model, the metastatic potential correlated with IGF-IR expression levels (29, 31). It was therefore of interest to determine whether SLPI expression was regulated by IGF-IR. To this end, SLPI expression levels were analyzed in M-27 cells overexpressing IGF-IR (M-27IGF-IR) and compared with those in wild-type cells. Results of mRNA and protein analyses (Fig. 1 ) showed an inverse correlation between the expression levels of SLPI and IGF-IR in these cells. We previously reported that IGF-IR overexpression in M-27 cells resulted in the acquisition of a liver-metastasizing potential (29, 31). The present results show that SLPI gene expression was in fact lost in these cells, confirming the inverse correlation between SLPI expression and the metastatic phenotype and identifying SLPI as an IGF-IR–regulated gene. Together, these data suggested that SLPI may be directly involved in the regulation of liver metastasis.


Figure 1
View larger version (14K):
[in this window]
[in a new window]
  		Figure 1. SLPI expression levels are inversely correlated to IGF-IR expression and the liver-metastasizing potential. A, representative data of RT-PCR analyses done on RNA extracted from the tumor cells and results of laser densitometry based on three experiments; columns, mean ratio of SLPI/GAPDH relative to H-59 cells that were assigned a value of 1 (left) or mean ratio of IGF-IR/GAPDH relative to M-27 cells that were assigned a value of 1 (right); bars, SD. B, to assess the SLPI protein expression level, Western blot analysis was done on 48-hour serum-free conditioned media obtained from the tumor cells and concentrated 40-fold before analysis.

 
Production and characterization of H-59 cells overexpressing SLPI. To determine whether SLPI expression was causally related to the protection against liver metastasis, we transfected H-59 cells with the pCDNA3.1-SLPI expression vector and several stable clones were selected in G418-containing medium. Using RT-PCR and Western blot analysis, we identified three clones (SLPI-1, SLPI-2, and SLPI-3) expressing SLPI mRNA (Fig. 2A ) and secreting high levels of the SLPI protein (Fig. 2B). As expected, mock-transfected H-59 clones (Mock-1 and Mock-2) had no detectable SLPI mRNA or protein expression (Fig. 2A and B).


Figure 2
View larger version (23K):
[in this window]
[in a new window]
  		Figure 2. H-59 cells transfected with the SLPI gene express SLPI transcripts and secrete the protein. A, total RNA was extracted from wild-type H-59 cells and from clonal sublines isolated from the mock-transfected (Mock-1 and Mock-2) and SLPI-transfected (SLPI-1, SLPI-2, and SLPI-3) populations of H-59 and analyzed by RT-PCR. Results of densitometry; columns, mean ratio of SLPI/GAPDH relative to H-59 cells that were assigned a value of 1. B, Western blot analysis was done on serum-free conditioned media harvested from the tumor cells and concentrated 100-fold. Cathepsin L, a protein secreted by H-59 cells (50) was used as a loading control. Results of densitometry; columns, ratio of SLPI/Cathepsin L relative to H-59 cells that were assigned a value of 1.

 
Assessment of the biological activity of SLPI produced by gene-transfected H-59 carcinoma cells. Previously, it has been reported that SLPI suppressed LPS-induced NF-{kappa}B activation and TNF-{alpha} and nitric oxide production in macrophages, suggesting that SLPI can inhibit the LPS induced responses via an autocrine mechanism (3). To determine whether SLPI-transfected cells produced functionally active SLPI protein, which is able to inhibit TNF-{alpha} production, we used an in vitro assay of macrophage activation. Serum-free conditioned media harvested from SLPI-transfected and control H-59 cells were added to monolayers of a murine macrophage cell line (ANA-1) 1 hour before the addition of LPS and the cultures were incubated for an additional 6 hours. TNF-{alpha} production was assessed in the macrophage supernatants using an ELISA. Nontreated LPS-activated macrophages were used as positive controls. Results in Fig. 3 show that whereas medium conditioned by H-59 cells had no effect, or even increased TNF-{alpha} production by the macrophages, medium conditioned by SLPI-expressing cells blocked TNF-{alpha} production, reducing it to background levels. This suggested that the cells produced a fully active SLPI, which is able to inhibit TNF-{alpha} production by macrophages. A similar effect was observed when medium conditioned by the SLPI-producing nonmetastatic M-27 cells was tested. TNF-{alpha} levels detectable in H-59 and M-27 conditioned medium were low (0.0205 and 0.0214 ng/mL, respectively) and comparable to those detected in control, nonstimulated ANA-1 cells (0.0205 ng/mL).


Figure 3
View larger version (21K):
[in this window]
[in a new window]
  		Figure 3. H-59 cells transfected with SLPI secrete a biologically active protein. ANA-1 cells were seeded in 24-well plates at a density of 5 x 105 per well and cultured for 1 hour. Twenty-four-hour serum-free conditioned media harvested from the tumor cell cultures were added to the ANA-1 monolayers 1 hour before the addition of 100 ng/mL LPS and the cultures were incubated for an additional 6 hours. ANA-1 culture media were collected and TNF-{alpha} levels analyzed in triplicates using an ELISA. Nonstimulated ANA-1 (ANA-1) conditioned medium was used as a control. **, P < 0.01; ***, P < 0.001, Student's t test.

 
SLPI expression inhibits TNF-{alpha} induction in the liver in response to infiltrating tumor cells. In a series of reports, we previously showed that the influx of metastatic tumor cells into the liver triggers a rapid proinflammatory response. Specifically, we found that Kupffer cell–associated TNF-{alpha} and IL-1 production were increased in response to the tumor cells and this led to up-regulated expression of E- and P-selectin, VCAM-1, and ICAM-1 on hepatic sinusoidal endothelial cells. This response was restricted to highly metastatic H-59 carcinoma cells and was not triggered by poorly metastatic M-27 cells (22, 25). To determine whether SLPI expression played a regulatory role in these divergent abilities to induce host reactivity, we compared the course of host inflammation induced by wild-type (nontransfected) H-59 cells to the inflammatory response induced by carcinoma cells stably expressing the SLPI gene. Using real-time PCR, we monitored hepatic TNF-{alpha} mRNA levels at different time intervals post intrasplenic/portal tumor inoculation. As shown in Fig. 4 , the inoculation of untransfected or mock-transfected H-59 cells triggered a time-dependent induction of TNF-{alpha} mRNA that was evident at 1 hour, peaked at 6 hours, and persisted for up to 10 hours post tumor cell injection. Saline-injected animals did not express TNF-{alpha} mRNA. Interestingly, H-59 carcinoma cells stably expressing SLPI also initially induced TNF-{alpha} mRNA synthesis in the inoculated mice but the expression was short-lived and was significantly reduced relative to mice injected with control cells by 6 hours post tumor cell inoculation.


Figure 4
View larger version (34K):
[in this window]
[in a new window]
  		Figure 4. SLPI expression inhibits TNF-{alpha} induction in the liver in response to infiltrating tumor cells. Mice were injected with 2 x 106 tumor cells by the intrasplenic/portal route and the livers were removed at the time intervals indicated. Total RNA was extracted and analyzed by real-time PCR and RT-PCR. A, representative data obtained by RT-PCR done on livers of animals injected with the indicated tumor cells. B, real-time PCR results. Columns, means of data obtained with H-59, pooled data for Mock-1 and Mock-2 cells (Mock), and pooled data for SLPI 1, SLPI-2, and SLPI-3 (SLPI) cells; bars, SD. For each of these clones, three livers were analyzed per each time point (n = 3 for H-59, n = 6 for Mock, and n = 9 for SLPI). The data were analyzed using the LightCycler software and normalized against GAPDH. **, P < 0.01; *, P < 0.05, Student's t test.

 
SLPI expression reduces E-selectin gene induction in the liver in response to infiltrating tumor cells. In agreement with our previous reports (22), vascular endothelial E-selectin mRNA expression in mice inoculated with H-59 cells began to increase within 2 hours, reaching maximal levels at 8 hours, and remaining high for up to 10 hours following tumor inoculation. A similar pattern was observed in mice inoculated with mock-transfected H-59 cells. In contrast, we found a weak and short-lived increase in E-selectin expression in mice injected with H-59 carcinoma cells expressing SLPI, with levels declining to the baseline as early as 8 hours following tumor inoculation (Fig. 5 ). Immunohistochemistry done on liver cryostat sections obtained from tumor-injected animals confirmed these differences in E-selectin induction by the tumor cells. Figure 5C illustrates representative images of vascular E-selectin staining obtained in livers from mice injected with GFP-expressing H-59 tumor cells (8 hours following injection). No immunostaining was observed in livers from mice injected with SLPI-1-transfected tumor cells. This rapid decline in TNF-{alpha} production and the subsequent E-selectin induction wer not due to a difference in the total number of cells retained in the liver following tumor inoculation, as determined by fluorescence microscopy analysis and shown in Fig. 5D.


Figure 5
View larger version (26K):
[in this window]
[in a new window]
  		Figure 5. SLPI expression reduces E-selectin gene induction in the liver in response to infiltrating tumor cells. Mice were inoculated with 2 x 106 tumor cells by the intrasplenic/portal route and the livers were removed at the time intervals indicated. Total RNA was extracted and analyzed by RT-PCR. For each of the cell types, three livers were analyzed per each time point and each analysis was done thrice. A, representative data. B, results of laser densitometry. Columns, means of the data obtained with H-59 (n = 3), Mock-1 and Mock-2 (Mock, n = 6), and SLPI-1, SLPI-2, and SLPI-3 (SLPI, n = 9) cells; bars, SD. They are expressed as the ratios of E-selectin/GAPDH relative to the control group (livers of saline injected mice), which were assigned a value of 1 (**, P < 0.01, Student's t test). C, results of immunohistochemistry done on cryostat sections of livers derived from the animals 8 hours following the injection of GFP-expressing nontransfected (left) or SLPI-transfected (right) H-59 cells. The sections were stained with rat anti-murine E-selectin antibodies and an Alexa 568 goat anti-rat antibody (red staining). Representative of 60 fields analyzed using the 40x objective. D, results of tumor cell quantification based on fluorescence microscopy analysis done on liver cryostat sections that were obtained at different intervals post injection of 106 GFP+ tumor cells. Columns, mean number of tumor cells observed using the 40x objective in a total of 80 fields, representing a total of four liver sections per time point (P > 0.05 at all time points); bars, SD.

 
Expression of IGF-IR increases TNF-{alpha} production in response to tumor cell injection. We previously reported that M-27 carcinoma cells transfected with the IGF-IR gene acquired a liver-metastasizing potential (29). We have shown here (Fig. 1) that these cells lose the expression of SLPI mRNA and do not produce detectable levels of the protein (Fig. 1). It was therefore of interest to test whether these cells could induce TNF-{alpha} synthesis in vivo on entry into the liver. To this end, the tumor cells were injected via the intrasplenic/portal route and at different intervals thereafter; hepatic TNF-{alpha} production was measured by RT-PCR. The results in Fig. 6 show that IGF-IR gene expression in these cells and the resulting loss of SLPI production restored the ability of the cells to induce TNF-{alpha} production in the liver to levels generally observed following the injection of highly metastatic H-59 cells.


Figure 6
View larger version (20K):
[in this window]
[in a new window]
  		Figure 6. Expression of IGF-IR increases TNF-{alpha} production in the liver in response to tumor cell injection. Mice were injected by the intraslenic/portal route with 2 x 106 tumor cells and the livers were removed at the time intervals indicated. Total RNA was extracted and analyzed by real-time PCR using the conditions described in the text. Three livers were analyzed per each time point and each sample was tested in three independent experiments. A, representative data from the RT-PCR analysis. B, results of real-time PCR analyzed using the LightCycler software. GAPDH was used as a loading control in both of these analyses. **, P < 0.01; *, P < 0.03, Student's t test.

 
Expression of SLPI prevents experimental liver metastasis. Finally, we tested the effect of SLPI secretion and the resulting loss of TNF-{alpha} and E-selectin induction on the ability of H-59 cells to colonize the liver. Tumor cells were inoculated by the intrasplenic/portal route and hepatic metastases were enumerated 14 to 21 days later. Results in Fig. 7 show that SLPI expression in H-59 cells altered their metastatic potential. In mice inoculated with H-59 cells that secreted SLPI, the number of hepatic metastases was reduced by 66% to 80% (P < 0.001) relative to wild-type cells and by 54% to 70% (P < 0.005) relative to mock-transfected cells. Results of a Matrigel invasion assay, shown in Fig. 7C, suggest that this reduction in the metastatic potential was not due to reduced cell invasion (29, 34).


Figure 7
View larger version (53K):
[in this window]
[in a new window]
  		Figure 7. Expression of SLPI prevents experimental liver metastasis. Liver metastases were enumerated 14 days after the intrasplenic/portal injection of 105 tumor cells. A, representative livers. B, results obtained with each individual cell type. Cumulative data from three independent experiments are shown. The median numbers of metastases/liver are indicated [P < 0.001 for mice injected with each of the SLPI clones and P < 0.005 for mice injected with the uncloned population of SLPI-transfected H-59 cells (H-59SLPI) as compared with mice injected with H-59 or mock-transfetced cells (Mann-Whitney test)]. The two latter groups did not significantly differ from each other. C, results of the Matrigel invasion assay. Columns, mean number of cells per field in three filters counted per tumor type and based on analysis of 20 random fields per filter; bars, SD.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Our results identify SLPI as an inhibitor of liver metastasis and link this function to its ability to suppress the tumor cell induced host proinflammatory response during the early stages of liver colonization. The host inflammatory response and its major mediator, TNF-{alpha}, play a dual role in tumor progression and metastasis. On one hand, TNF-{alpha} can inhibit tumor growth through its cytocidal and proapoptotic activities (35), but on the other hand, it can promote tumor progression through several alternate mechanisms that include promotion of tumor cell growth (36), induction of tumor cell motility and invasion (20, 37, 38), up-regulation of vascular endothelial cell adhesion receptors as shown by us and others (22, 23, 39), and the induction of angiogenesis (13, 40, 41). The ultimate effect of TNF-{alpha} may depend on its concentrations, on tumor cell susceptibility to its proapoptotic effects, and on the stage of the disease at which the tumor and its microenvironment are subject to its actions (12–14, 42).

Our results suggest that the response of host inflammatory cells in the liver, Kupffer cells in particular, may be modulated in a paracrine fashion by tumor-derived soluble factors that can either induce or attenuate cytokine production. Indeed, both autocrine and paracrine effects of SLPI in inflammation have been described. SLPI was initially identified as a macrophage-secreted protein that attenuates LPS-induced nitric oxide and TNF-{alpha} production in an autocrine fashion (8). Transfection of macrophages with a eukaryotic expression vector encoding SLPI cDNA (3) or using adenoviral gene delivery (9) resulted in the inhibition of LPS-induced TNF-{alpha} production by the transfected cells. In vivo production of both local and systemic SLPI in response to bacterial infection has been well documented. Moreover, in a model of hepatic ischemia/reperfusion induced in mice by partial hepatectomy, the exogenous administration of SLPI was shown to attenuate liver and lung inflammatory injury, diminish neutrophil accumulation in both organs, and reduce serum levels of TNF-{alpha} and macrophage inflammatory protein 2, suggesting that SLPI can act in a paracrine fashion to attenuate inflammation-induced damage in sites remote from the site of the inflammatory insult (43, 44). The present results show that high endogenous SLPI production by poorly metastatic M-27 carcinoma cells or SLPI-transfected H-59 cells led to reduced TNF-{alpha} production in the liver as compared with control, highly metastatic H-59 cells. These findings, taken together with our previous results, suggest that in the present model, tumor-derived SLPI was acting in a paracrine fashion to block cytokine production by Kupffer cells localized in sinusoidal vessels around the incoming tumor cells.

The liver is the major endocrine source of IGF-I production. Previously, we have shown that hepatic IGF-I acts as a paracrine, growth-promoting factor to enhance the growth of metastatic H-59 cells in the liver (32, 33). The present data show that in addition to its growth promoting effect, IGF-I may also regulate the tumor-induced inflammatory response by suppressing SLPI production, thereby allowing sufficient local TNF-{alpha} levels to be produced and initiate the molecular cascade required for metastases formation. IGF-I may also act as a survival factor, protecting the tumor cells, as well as resident hepatic cells, from TNF-{alpha}-induced apoptosis (45–47).

The mechanism underlying the negative regulatory effect of IGF-IR on SLPI transcription remains to be elucidated. The transcriptional activators of SLPI synthesis are yet to be defined. The identification of LPS as an inducer of both TNF-{alpha} and SLPI implies that SLPI synthesis may be regulated by NF-{kappa}B. In glial cells, IGF-I was identified as an inhibitor of NF-{kappa}B activation and this was mediated through serine phosphorylation of I{kappa}B{alpha} (48). The inhibition of NF-{kappa}B-mediated signaling may be one mechanism by which a negative regulatory effect on SLPI production is transmitted.

To date, few studies have examined the role of SLPI in tumorigenesis and metastasis. Interestingly, however, it was recently reported that elevated levels of SLPI increased both the s.c. growth and the lung-colonizing potential of 3LL cells, and this was attributed to the protease inhibitory function of SLPI (49). Whereas the reason for the discrepancy between these and our own results is not presently clear, it may be related to the different anatomic sites used to evaluate tumor growth in the two studies (i.e., s.c. and lung metastases in one and liver metastases in the other). It is conceivable that SLPI and, consequently, TNF-{alpha} and inflammation play different and even opposing regulatory roles in tumor growth in these sites. IGF-IR expression levels in the tumor cells used in the different studies may also have contributed to the divergent results by affecting their susceptibility to TNF-{alpha}-induced apoptosis. This interpretation seems to be in agreement with our findings that a reduction in IGF-IR expression in H-59 cells by antisense RNA reduced their liver-metastasizing potential but not their s.c. growth (33). It is of interest to note in this respect that M-27 cells can metastasize spontaneously to the lung but not to the liver (26). These site-specific growth patterns indicate that SLPI and IGF-IR expression may differently affect tumor growth in different anatomic sites, possibly because the host inflammatory responses generated in these sites are distinct or they could affect tumor progression in diverse ways.

Our results, taken together with previous studies, provide further evidence that the host inflammatory response, through its molecular mediators, such as TNF-{alpha} and SLPI, plays a crucial role in regulating the tumor microenvironment and thereby may control the fate of disseminating tumor cells.


   Acknowledgments
 
Grant support: Canadian Institute for Health Research grants MOP-13646 (P. Brodt) and MOP-36337 (D. Radzioch), National Cancer Institute of Canada Terry Fox Frontiers Initiative Grant (P. Brodt), NIH grants AI30165 and GM61710 (A. Ding), and Valorization Recherche Québec grant and a Cedar Cancer Institute fellowship (N. Wang).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Drs. Patrick Auguste (Institut National de la Sante de la Recherche Medicale, University Bordeaux, France) and Hana Friedman (Molecular Oncology Group, McGill University) for technical advice and assistance, and Dr. Jacques Genest (Department of Cardiology, McGill University) for the use of the alpha imager.

Received 7/29/05. Revised 11/ 7/05. Accepted 12/22/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 1991;87:2207–15.[Medline]
  2. Franken C, Meijer CJ, Dijkman JH. Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 1989;37:493–8.[Abstract]
  3. Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997;88:417–26.[CrossRef][Medline]
  4. Boudier C, Cadene M, Bieth JG. Inhibition of neutrophil cathepsin G by oxidized mucus proteinase inhibitor. Effect of heparin. Biochemistry 1999;38:8451–7.[CrossRef][Medline]
  5. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995;96:456–64.[Medline]
  6. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996;64:4520–4.[Abstract]
  7. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997;99:894–900.[Medline]
  8. Jin F, Nathan CF, Radzioch D, Ding A. Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun 1998;66:2447–52.[Abstract/Free Full Text]
  9. Henriksen PA, Hitt M, Xing Z, et al. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-{kappa}B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 2004;172:4535–44.[Abstract/Free Full Text]
  10. Odaka C, Mizuochi T, Yang J, Ding A. Murine macrophages produce secretory leukocyte protease inhibitor during clearance of apoptotic cells: implications for resolution of the inflammatory response. J Immunol 2003;171:1507–14.[Abstract/Free Full Text]
  11. Lentsch AB, Jordan JA, Czermak BJ, et al. Inhibition of NF-{kappa}B activation and augmentation of I{kappa}Bß by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 1999;154:239–47.[Abstract/Free Full Text]
  12. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211–7.[CrossRef][Medline]
  13. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002;13:135–41.[CrossRef][Medline]
  14. Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-{alpha} in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004;4:314–20.[CrossRef][Medline]
  15. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-{alpha} are resistant to skin carcinogenesis. Nat Med 1999;5:828–31.[CrossRef][Medline]
  16. Orosz P, Kruger A, Hubbe M, Ruschoff J, Von Hoegen P, Mannel DN. Promotion of experimental liver metastasis by tumor necrosis factor. Int J Cancer 1995;60:867–71.[Medline]
  17. Stoelcker B, Hafner M, Orosz P, Nieswandt B, Mannel DN. Role of adhesion molecules and platelets in TNF-induced adhesion of tumor cells to endothelial cells: implications for experimental metastasis. J Inflamm 1995;46:155–67.[Medline]
  18. Orr FW, Wang HH. Tumor cell interactions with the microvasculature: a rate-limiting step in metastasis. Surg Oncol Clin N Am 2001;10:357–81, ix–x.[Medline]
  19. Wang HH, McIntosh AR, Hasinoff BB, et al. Regulation of B16F1 melanoma cell metastasis by inducible functions of the hepatic microvasculature. Eur J Cancer 2002;38:1261–70.[Medline]
  20. Arnott CH, Scott KA, Moore RJ, et al. Tumour necrosis factor-{alpha} mediates tumour promotion via a PKC {alpha}- and AP-1-dependent pathway. Oncogene 2002;21:4728–38.[CrossRef][Medline]
  21. Brodt P, Fallavollita L, Bresalier RS, Meterissian S, Norton CR, Wolitzky BA. Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer 1997;71:612–9.[CrossRef][Medline]
  22. Khatib AM, Kontogiannea M, Fallavollita L, Jamison B, Meterissian S, Brodt P. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res 1999;59:1356–61.[Abstract/Free Full Text]
  23. Khatib AM, Fallavollita L, Wancewicz EV, Monia BP, Brodt P. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res 2002;62:5393–8.[Abstract/Free Full Text]
  24. Sturm JW, Magdeburg R, Berger K, et al. Influence of TNFA on the formation of liver metastases in a syngenic mouse model. Int J Cancer 2003;107:11–21.[CrossRef][Medline]
  25. Khatib AM, Auguste P, Fallavollita L, et al. Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol 2005;167:749–59.[Abstract/Free Full Text]
  26. Brodt P. Characterization of two highly metastatic variants of Lewis lung carcinoma with different organ specificities. Cancer Res 1986;46:2442–8.[Abstract/Free Full Text]
  27. Samani AA, Chevet E, Fallavollita L, Galipeau J, Brodt P. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res 2004;64:3380–5.[Abstract/Free Full Text]
  28. Cox GW, Mathieson BJ, Gandino L, Blasi E, Radzioch D, Varesio L. Heterogeneity of hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus infection of bone marrow or fetal liver. J Natl Cancer Inst 1989;81:1492–6.[Abstract/Free Full Text]
  29. Brodt P, Fallavollita L, Khatib AM, Samani AA, Zhang D. Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor ß subunit. J Biol Chem 2001;276:33608–15.[Abstract/Free Full Text]
  30. Gosselin D, DeSanctis J, Boule M, Skamene E, Matouk C, Radzioch D. Role of tumor necrosis factor {alpha} in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect Immun 1995;63:3272–8.[Abstract]
  31. Long L, Rubin R, Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 1998;238:116–21.[CrossRef][Medline]
  32. Long L, Nip J, Brodt P. Paracrine growth stimulation by hepatocyte-derived insulin-like growth factor-1: a regulatory mechanism for carcinoma cells metastatic to the liver. Cancer Res 1994;54:3732–7.[Abstract/Free Full Text]
  33. Long L, Rubin R, Baserga R, Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995;55:1006–9.[Abstract/Free Full Text]
  34. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003;22:974–82.[CrossRef][Medline]
  35. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628–33.[CrossRef][Medline]
  36. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-{kappa}B in cancer cells converts inflammation-induced tumor growth mediated by TNF{alpha} to TRAIL-mediated tumor regression. Cancer Cell 2004;6:297–305.[CrossRef][Medline]
  37. Malik ST, Griffin DB, Naylor MS, Fiers W, Oliff A, Balkwill FR. The complex effects of recombinant tumour necrosis factor-{alpha} (rhTNF-{alpha}) in human ovarian cancer xenograft models. Prog Clin Biol Res 1990;349:393–403.[Medline]
  38. Malik ST, Naylor MS, East N, Oliff A, Balkwill FR. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 1990;26:1031–4.[Medline]
  39. Kitakata H, Nemoto-Sasaki Y, Takahashi Y, Kondo T, Mai M, Mukaida N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res 2002;62:6682–7.[Abstract/Free Full Text]
  40. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-{alpha}. Nature 1987;329:630–2.[CrossRef][Medline]
  41. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor {alpha}-dependent angiogenesis. Mol Cell Biol 1997;17:4015–23.[Abstract]
  42. Szlosarek PW, Balkwill FR. Tumour necrosis factor {alpha}: a potential target for the therapy of solid tumours. Lancet Oncol 2003;4:565–73.[CrossRef][Medline]
  43. Lentsch AB, Yoshidome H, Warner RL, Ward PA, Edwards MJ. Secretory leukocyte protease inhibitor in mice regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion. Gastroenterology 1999;117:953–61.[CrossRef][Medline]
  44. Lentsch AB, Ward PA. Understanding the pathogenesis of inflammation using rodent models: identification of a transcription factor (NF{kappa}B) necessary for development of inflammatory injury. Ilar J 1999;40:151–6.[Medline]
  45. Galvan V, Logvinova A, Sperandio S, Ichijo H, Bredesen DE. Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1). J Biol Chem 2003;278:13325–32.[Abstract/Free Full Text]
  46. Ying Wang J, Peruzzi F, Lassak A, et al. Neuroprotective effects of IGF-I against TNF{alpha}-induced neuronal damage in HIV-associated dementia. Virology 2003;305:66–76.[CrossRef][Medline]
  47. Byrne AT, Southgate J, Brison DR, Leese HJ. Effects of insulin-like growth factors I and II on tumour-necrosis-factor-{alpha}-induced apoptosis in early murine embryos. Reprod Fertil Dev 2002;14:79–83.[CrossRef][Medline]
  48. Pons S, Torres-Aleman I. Insulin-like growth factor-I stimulates dephosphorylation of I{kappa}B through the serine phosphatase calcineurin (protein phosphatase 2B). J Biol Chem 2000;275:38620–5.[Abstract/Free Full Text]
  49. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A 2003;100:5778–82.[Abstract/Free Full Text]
  50. Zhang D, Bar-Eli M, Meloche S, Brodt P. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem 2004;279:19683–90.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
F. A. Simpkins, N. M. Devoogdt, N. Rasool, N. E. Tchabo, E. U. Alejandro, M. M.R.N. Kamrava, and E. C. Kohn
The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells
Carcinogenesis, March 1, 2008; 29(3): 466 - 472.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
P. Auguste, L. Fallavollita, N. Wang, J. Burnier, A. Bikfalvi, and P. Brodt
The Host Inflammatory Response Promotes Liver Metastasis by Increasing Tumor Cell Arrest and Extravasation
Am. J. Pathol., May 1, 2007; 170(5): 1781 - 1792.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Lundholm, U. Korner, L. Gunnebo, P. Sixt-Ammilon, M. Fouladiun, P. Daneryd, and I. Bosaeus
Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning
Clin. Cancer Res., May 1, 2007; 13(9): 2699 - 2706.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Devoogdt, H. Revets, A. Kindt, Y. Q. Liu, P. De Baetselier, and G. H. Ghassabeh
The Tumor-Promoting Effect of TNF-{alpha} Involves the Induction of Secretory Leukocyte Protease Inhibitor
J. Immunol., December 1, 2006; 177(11): 8046 - 8052.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, N.
Right arrow Articles by Brodt, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, N.
Right arrow Articles by Brodt, P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online